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Abstract
Background: High baseline levels of IP-10 predict a slower first phase decline in HCV RNA and a poor outcome following
interferon/ribavirin therapy in patients with chronic hepatitis C. Several recent studies report that single nucleotide
polymorphisms (SNPs) adjacent to IL28B predict spontaneous resolution of HCV infection and outcome of treatment among
HCV genotype 1 infected patients.
Methods and Findings: In the present study, we correlated the occurrence of variants at three such SNPs (rs12979860,
rs12980275, and rs8099917) with pretreatment plasma IP-10 and HCV RNA throughout therapy within a phase III treatment
trial (HCV-DITTO) involving 253 Caucasian patients. The favorable SNP variants (CC, AA, and TT, respectively) were associated
with lower baseline IP-10 (P = 0.02, P = 0.01, P = 0.04) and were less common among HCV genotype 1 infected patients than
genotype 2/3 (P,0.0001, P,0.0001, and P= 0.01). Patients carrying favorable SNP genotypes had higher baseline viral load
than those carrying unfavorable variants (P = 0.0013, P = 0.029, P = 0.0004 respectively). Among HCV genotype 1 infected
carriers of the favorable C, A, or T alleles, IP-10 below 150 pg/mL significantly predicted a more pronounced reduction of
HCV RNA from day 0 to 4 (first phase decline), which translated into increased rates of RVR (62%, 53%, and 39%) and SVR
(85%, 76%, and 75% respectively) among homozygous carriers with baseline IP-10 below 150 pg/mL. In multivariate
analyses of genotype 1-infected patients, baseline IP-10 and C genotype at rs12979860 independently predicted the first
phase viral decline and RVR, which in turn independently predicted SVR.
Conclusions: Concomitant assessment of pretreatment IP-10 and IL28B-related SNPs augments the prediction of the first
phase decline in HCV RNA, RVR, and final therapeutic outcome.
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Introduction
Hepatitis C virus (HCV) infects 170 million people worldwide [1]
and is a leading cause of chronic hepatitis, cirrhosis, and hepatocellular
carcinoma [2]. Treatment with pegylated interferon-a (peg-IFN) and
ribavirin results in a sustained viral response (SVR) in approximately
50% of patients infected with HCV of genotype 1 and 80% of those
with HCV genotypes 2 or 3 [3,4,5]. Recently, several genome-wide
association studies have revealed that single nucleotide polymorphisms
(SNPs) in the 19q13 region, in close proximity to three genes (IL28A,
IL28B, and IL29) encoding cytokines of the IFN-l (i.e. type III IFN)
family, predict spontaneous clearance of HCV infection [6,7] as well as
SVR following peg-IFN/ribavirin therapy among patients infected
with HCV genotype 1 [6,8,9,10]. Three of these SNPs are reportedly
highly predictive of a favorable treatment response among HCV
genotype 1 infected patients: rs12979860 [7,8], rs12980275 [10],
and rs8099917 [6,9,10], with a strong linkage disequilibrium noted
between rs12979860 and rs8099917 [6]. Aside from differences
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in the assays utilized, SVR was the defined endpoint in the genome-
wide association study (GWAS) identifying rs12979860 [8], whereas
null responsiveness to interferon was used in the analysis that endorsed
rs12980275 and rs8099917 [10].
The C allele at rs12979860 also is associated with higher
baseline viral load [8,11], which otherwise is an established
negative predictor of response to peg-IFN/ribavirin therapy
[3,4,5]. Similarly counterintuitive is the report that a C allele at
rs12979860 is more common in Caucasians with HCV genotype 2
and 3 infection than in genotype 1 infected or in HCV uninfected
individuals [11,12]. In addition, two studies reported that
homozygous carriage of GG at rs8099917 was associated with
slightly lower PBMC mRNA expression of IL28 in 49 and 20
individuals, respectively [9,10], although another study reported
no difference in IL28B mRNA expression when stratified
regarding rs12979860 genotype in PBMC from 80 individuals
[8]. In line with this latter finding, G allele carriage at rs8099917
has been reported to be associated with elevated intrahepatic
mRNA expression of a panel of 37 interferon-stimulated genes
(ISGs) but not IL28B in 91 HCV infected patients [13].
Interferon-gamma inducible protein 10 kDa (IP-10 or CXCL10)
is a chemotactic CXC chemokine of 77 amino acids in its mature
form [14,15]. IP-10 targets the CXCR3 receptor but, unlike other
CXC chemokines, lacks chemotactic activity for neutrophils and
instead attracts T lymphocytes, NK cells, and monocytes to sites of
infection [15,16,17]. IP-10 is produced by a variety of cells,
including hepatocytes, and levels of IP-10 at onset of therapy are
reportedly elevated in patients infected with HCV of genotypes 1 or
4 who do not achieve SVR [18]. In difficult-to-treat genotype 1
infected HCV patients, cut-off levels of IP-10 in plasma of 150 pg/
mL (approximately equal to 2 standard deviations above the mean
IP-10 level of HCV seronegative blood donors) and 600 pg/mL
have yielded positive and negative predictive values for SVR of 71%
and 100%, respectively [19]. IP-10 in plasma is mirrored by
intrahepatic IP-10 mRNA, and strongly predicts the HCV RNA
decline during the first days (‘‘first phase decline’’) during
interferon/ribavirin therapy for all HCV genotypes [20].
The impact of IP-10 on the elimination of HCV RNA during
therapy in the setting of IL28B genetic variants is not known. We
therefore assessed plasma IP-10 in relation to genetic variants at
three major IL28B SNPs (rs12979860, rs12980275, and rs8099917)
in patients chronically infected with HCV genotypes 1-4. Our
results demonstrate a significant association between IL28B
genetic variants and IP-10 in plasma and imply that combined
assessment of these predictive factors may improve prognostication
of the rate of first phase elimination of HCV RNA, as well as
achieving a rapid virological response (RVR) and SVR.
Methods
Ethical Aspects
The treatment study conformed to the guidelines of the 1975
Declaration of Helsinki and was approved by ethical committees at
each center (Medicinska fakultetens forskningsetikkommitte´,
Go¨teborgs Universitet, Gothenburg, Sweden, CPP-Ile-de-France
IX, CHU Henri Mondor, Creteil, France, Comitato Etico
Indipendente (IRB/IEC) dell’Azienda Ospedaliera di Parma,
Parma, Italy, Comite d’Ethique du department de Medicine,
Hopitaux Universitaires de Gene`ve, Geneva, Switzerland, the
Helsinki committee of the Kaplan Medical Center, Rehovot,
Israel, the Ethics Committee of Hospital General Vall d’Hebron,
Barcelona, Spain, the Ethics Committee of Aristotle University of
Thessaloniki, Thessaloniki, Greece, the Ethics Committee of
Klinikum der Johann Wolfgang Goethe-Universitat, Frankfurt,
Germany, the Ethics Committee of University Hospital Rotter-
dam Dijkzigt, Rotterdam, Netherlands). Written informed consent
was obtained from each patient included in this study.
Patients
Between February 2001 and November 2003, 270 patients (180
men and 90 women) were recruited in a phase III, open-label,
randomized, multicenter trial conducted by the DITTO-HCV
study group at 9 centers in France, Germany, Greece, Israel, Italy,
Netherlands, Spain, Sweden, and Switzerland, as previously
Table 1. Baseline Characteristics with Patients Grouped According to IL28B Genetic Variations.
NCBI dbSNP ID rs12979860 rs12980275 rs8099917
CC CT TT P AA AG GG P TT TG GG P
(n=93) (n =123) (n=37) (n =101) (n =115) (n=37) (n =153) (n =90) (n=10)
Age (years)a 41.6
(10.1)
41.9
(9.5)
41.9
(11.4)
0.85c 41.7
(10.1)
41.8
(10.3)
41.0
(11.5)
0.93c 42.1
(9.2)
40.5
(11.1)
45.0
(12.5)
0.23c
Gender
(Male/Female)b
64/29 77/46 28/8 0.18d 65/36 78/37 26/10 0.62d 102/51 60/29 7/3 0.97d
BMI
(kg/m2)a
25.1
(3.6)
25.0
(3.5)
25.0
(3.5)
0.91c 24.9
(3.7)
25.3
(3.7)
25.1
(3.3)
0.69c 25.1
(3.6)
25.1
(3.5)
26.3
(4.1)
0.55c
HCV-RNA level
(log10 IU/mL)
a
6.3 (0.8) 6.1 (0.7) 5.9 (0.8) 0.0013c 6.3 (0.8) 6.1 (0.8) 6.0 (0.6) 0.029c 6.3 (0.8) 5.9
(0.7)
5.8
(0.8)
0.0004c
HCV Genotype
(1/2/3/4)b
44/13/
33/3
96/7/
15/5
30/3/
1/3
,0.0001d 52/13/
33/3
88/7/
15/5
30/3/
1/3
,0.0001d 97/15/
38/3
66/7/
11/6
7/1/
0/2
0.01d
Fibrosis Stage
(Ishak 0/1/2/3/4/5/6)b
3/18/27/
11/5/12/5
7/35/27/
17/7/6/6
1/8/11/
2/3/2/3
0.5d 4/22/28/
12/6/12/4
6/31/25/
16/6/6/7
1/8/12/
2/3/2/3
0.71d 6/36/46/
22/7/14/5
5/22/17/
8/8/5/7
0/3/2/
0/0/1/2
0.18d
Steatosis Grade
(0/1/2/3)b
31/33/
12/5
54/35/
14/1
13/13/
3/1
0.35d 35/35/
13/5
48/33/
13/2
15/13/
3/0
0.54d 60/53/
16/7
35/24/
12/0
3/4/
1/0
0.43d
aData presented as mean (SD) or
bn.
cKruskal-Wallis Test.
dChi Squared test.
doi:10.1371/journal.pone.0017232.t001
IP-10 and IL28B in Chronic Hepatitis C
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reported [21]. All patients were adults, had compensated liver
disease, were treatment naı¨ve for hepatitis C, and fulfilled the
following inclusion criteria: a positive test for anti-HCV antibody,
an HCV RNA level greater than 1000 IU/mL, and two serum
alanine aminotransferase values above the upper limit of normal
within 6 months of treatment initiation. Two hundred and fifty
three Caucasian patients had samples available for IL28B analysis
(baseline characteristics shown in Table 1), and 252 of these patients
had pretreatment plasma available for evaluation of IP-10.
Treatment
All patients in the DITTO-HCV trial were treated for 6 weeks
with 180 mg pegylated interferon-a2a sc once weekly (Pegasys, F.
Hoffmann-LaRoche, Basel, Switzerland) and ribavirin orally
twice daily (Copegus, F. Hoffmann-LaRoche) at a total daily dose
of 1,000 mg for patients weighing less than 75 kg and 1,200 mg
daily for above 75 kg. Thereafter, patients were randomized 1:1
based on their viral kinetic classification to receive individualized
therapy or to continue on standard combination therapy for a
total of 48 weeks. There were no major differences in treat-
ment outcome for patients receiving individualized or standard
therapy [21].
HCV Genotyping
Genotyping of HCV was performed using INNO-LiPA HCV II
(Innogenetics N.V., Ghent, Belgium).
Figure 1. Frequency distribution of IL28B variants in relation to HCV genotypes 1-3.
doi:10.1371/journal.pone.0017232.g001
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HCV RNA Quantification
HCV RNA was determined by RT-PCR using Cobas Amplicor
HCV Monitor version 2.0 (Roche Diagnostics, Branchburg, NJ),
and quantified on days 0, 1, 4, 7, 8, 15, 22, 29, at end of treatment,
and 24 months after the completion of treatment.
Classification of Treatment Outcome
Patients were classified as having achieved RVR if HCV
RNA was undetectable (,50 IU/mL) in plasma on treat-
ment day 29, and were classified as having SVR if HCV
RNA was undetectable in plasma 24 weeks after the completion
of therapy.
Liver Biopsies
Liver biopsies were obtained from patients in the DITTO-
HCV trial within 12 months prior to inclusion in the study, and
liver biopsy samples were processed for both histological
evaluation ($1.5 cm) and for RNA analysis ($1 cm). Only
biopsies with a length exceeding 1.5 cm and containing more
than 6 portal tracts were evaluated. In total, liver biopsies from
228 infected patients in the DITTO-HCV trial were retrieved
and evaluated. For each biopsy, a hematoxylin-eosin stain and a
Sirius Red stain were centrally staged and graded by two
independent observers experienced in pseudo-numerical scoring
of liver biopsies in a blinded fashion according to the Ishak
protocol [22]. Equivocal issues were debated after the indepen-
dent scores were noted, and a consensus score was obtained. In
addition, steatosis was graded as follows: absent = 0, less than
30% of hepatocytes involved = 1, 30–70% of hepatocytes
involved = 2, and more than 70% of hepatocytes involved = 3
[23].
IP-10 Quantification in Plasma
Quantification of IP-10 was performed using Quantikine (R&D
SYSTEMS Minneapolis, MN), a solid-phase ELISA, on plasma
samples obtained during the week prior to the start of therapy. All
samples were stored at –70uC until assayed.
DNA extraction
DNA from peripheral blood mononuclear cells was isolated
using the QIAamp DNA mini kit (Qiagen) and quantitated on the
NanoDrop 1000 spectrophotometer (Thermo Fischer Scientific).
IL28-B genotyping
DNA samples from patients and controls were genotyped for the
IL28B rs8099917, rs12979860 and rs12980275 polymorphism with
TaqMan SNP genotyping assays (Applied Biosystems Inc, Foster
City, CA), using the ABI 7500 Fast real time thermocycler, according
to manufacturers recommended protocols. TaqMan probes and
primers were designed and synthesized by Applied Biosystems Inc.
Automated allele calling was performed using SDS software from
Applied Biosystems Inc. Positive and negative controls were used in
each genotyping assay. The primers and probes utilized were:
1. NCBI dbSNP ID rs8099917 Applied Biosystems (AB)
reference: C_11710096_10
2. NCBI dbSNP ID rs12979860 Forward primer:TGTACTG-
AACCAGGGAGCTC, Reverse primer: GCGCGGAGT-
GCAATTCAAC, Vic probe: TGGTTCGCGCCTTC, Fam
probe: TGGTTCACGCCTTC
3. NCBI dbSNP ID rs12980275 Forward primer: GTGCTG-
AGAGAAGTCAAATTCC, Reverse primer: CCGCTA-
CCCGGCAAATATT, Vic probe: AGACACGTCTGTTTC-
TA, Fam probe: ACACGTCCGTTTCTA
Statistical Methods
Individual characteristics between groups were evaluated using
the Wilcoxon-Mann-Whitney U-test, Kruskal-Wallis test and Chi
squared (x2) test, and Spearman’s rank correlation coefficient rs
test was utilized to evaluate relationships between variables. All
abovementioned statistical analyses were performed using Stat-
View for Macintosh (Version 5.0, SAS Institute Inc., Cary, NC,
USA). After univariate analyses, multivariate analyses were
performed among the HCV genotype 1 infected patients using
Figure 2. Tenth, 25th, 50th, 75th, and 90th percentiles of pretreatment IP-10 in relation to IL28B variants.
doi:10.1371/journal.pone.0017232.g002
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Stata (version 9.1, StataCorp, College Station, TX, USA). For
multivariate models, all variables associated with the endpoint
(P,0.2) were entered, with age and gender forced into the model.
Because of strong linkage disequilibrium noted between
rs12979860 and rs12980275 (R2 = 0.86 assuming Hardy-Weinberg
equilibrium, as compared to R2 = 0.42 for rs12979860 and
rs8099917 as well as R2 = 0.41 for rs12980275 and rs8099917)
and because rs8099917 was not significantly associated with SVR,
only SNP variants for rs12979860 were included in the
multivariate analyses. SNPs were tested using three models
assuming one of the following modes of inheritance: dominant
(comparing presence of one or two copies of the minor allele versus
none), recessive (comparing presence of two copies of the minor
allele versus none or one copy), and additive (none, one or two
copies of the minor allele were coded 0, 1 and 2, respectively,
assuming greater effect with increased copy number of the minor
Figure 3. Correlation between IP-10 and first phase decline in IL28B variants among HCV genotype 1 patients.
doi:10.1371/journal.pone.0017232.g003
IP-10 and IL28B in Chronic Hepatitis C
PLoS ONE | www.plosone.org 5 February 2011 | Volume 6 | Issue 2 | e17232
allele). Linkage disequilibrium was calculated using the pwld
software implemented in Stata. All reported p-values are two-
sided, and p-values ,0.05 were considered significant.
Results
A strong association was noted between the distribution of HCV
genotypes and IL28B SNP variants (P,0.0001 for rs12979860 and
rs12980275, and P = 0.01 for rs8099917, Chi squared test; Table 1)
with the favorable CC at rs12979860, AA at rs12980275, and TT
at rs8099917 being significantly more common in patients with
HCV genotype 2 or 3 infection than genotype 1 (Figure 1). The 11
patients infected with HCV genotype 4 had a similar distribution
of IL28B variants as patients infected with genotype 1. Patients
who were homozygous for the favorable SNP genotypes had
higher baseline viral load (mean 6.3 log10 IU/mL; Table 1);
heterozygous patients had intermediate (mean 6.1 log10 IU/mL
for rs12979860 and rs12980275, and 5.9 log10 IU/mL for TG at
rs8099917); and patients who were homozygous for the risk alleles
had lower (mean 5.9 log10 IU/mL for TT at rs12979860, 6.0 log10
IU/mL for GG at rs12980275, and 5.8 log10 IU/mL for GG at
rs8099917, P = 0.0013, P = 0.029, and P = 0.0004 respectively;
Table 1).
Significantly lower baseline plasma IP-10 levels were observed
in homozygous carriers of the favorable CC at rs12979860
(median 189 vs. 258 pg/mL, P = 0.02, Mann-Whitney U-test;
Figure 2), AA at rs12980275 (median 189 vs. 258 pg/mL,
P = 0.01), and TT at rs8099917 (median 224 vs. 288 pg/mL,
P = 0.04), as compared with patients carrying one or two copies of
the risk alleles.
Among genotype 1 infected patients, homozygous carriers of the
three favorable IL28B alleles had significantly more pronounced
first phase viral decline, as reflected by the reduction of HCV
RNA from treatment day 0 to 4, when compared with patients
Figure 4. Mean HCV RNA reduction according to IP-10 in HCV genotype 1 with favorable IL28B genotype.
doi:10.1371/journal.pone.0017232.g004
Table 2. The impact of IL28B genetic variations and baseline plasma IP-10 on the likelihood of achieving RVR among patients
infected with HCV genotype 1.
NCBI dbSNP ID ,150 pg/mL 150–600 pg/mL .600 pg/mL P Total Pa
rs12979860
CC 8/13 (62%) 8/25 (32%) 0/4 (0%) 0.05 16/42 (38%) 0.006
CT 4/22 (18%) 11/55 (20%) 0/16 (0%) 0.15 15/93 (16%)
TT 0/6 (0%) 3/17 (18%) 0/3 (0%) 0.41 3/27 (11%)
rs12980275
AA 9/17 (53%) 9/29 (31%) 0/4 (0%) 0.10 18/50 (36%) 0.007
AG 3/19 (16%) 10/51 (20%) 0/15 (0%) 0.18 13/85 (15%)
GG 0/5 (0%) 3/17 (18%) 0/4 (0%) 0.41 3/27 (11%)
rs8099917
TT 11/28 (39%) 13/53 (25%) 0/14 (0%) 0.02 24/95 (25%) 0.18
TG 1/12 (8%) 9/40 (22%) 0/8 (0%) 0.20 10/61 (16%)
GG 0/1 (0%) 0/4 (0%) 0/1 (0%) 0/6 (0%)
Total 12/41 (29%) 22/97 (23%) 0/23 (0%) 0.02
All P-values using Chi squared test.
aP-values for SNP genotypes and frequency of RVR irrespective of baseline IP-10.
doi:10.1371/journal.pone.0017232.t002
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carrying the risk alleles (mean 2.0, 0.9 and 0.6 log10 IU/mL for
rs12979860 CC, CT and TT, 1.8, 0.9 and 0.7 log10 IU/mL for
rs12980275 AA, AG and TT, and 1.4, 0.8 and 0.6 for rs8099917
TT, TG and GG respectively, P,0.0001 for all 3 SNPs; Kruskal-
Wallis test). Among homozygous or heterozygous carriers of the
favorable alleles, IP-10 was highly significantly associated with the
first phase reduction of HCV RNA (rs =20.50, P = 0.001 and
rs =20.40, P,0.0001 for rs12979860 CC and CT, rs =20.29,
P = 0.04 and rs =20.39, P = 0.0003 for rs12980275 AA and AG,
and rs =20.40, P,0.0001 and rs =20.25, P = 0.046 for rs8099917
TT and TG respectively; Figure 3). This association was also
significant for the maximum decline in HCV RNA from day 0 to 4
as well as the decline from day 0 to 1, thus emphasizing an
association with the first phase decline in HCV RNA, and
translated into a more rapid reduction of HCV RNA during the
first 4 weeks of therapy among patients with lower baseline IP-10,
and a slower decline among those with higher (Figure 4). Similarly,
among genotype 2/3 infected patients, CC carriers of rs12979860
had significantly more pronounced first phase viral decline, as
reflected by the reduction of HCV RNA from treatment day 0 to
Figure 5. SVR rates in HCV genotype 1 according to IL28B variants and baseline IP-10.
doi:10.1371/journal.pone.0017232.g005
IP-10 and IL28B in Chronic Hepatitis C
PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e17232
4, when compared with patients carrying the risk allele (mean 2.7,
2.1 and 1.6 log10 IU/mL for CC, CT and TT, P = 0.04; Kruskal-
Wallis test) and IP-10 was significantly correlated with the
reduction in HCV RNA from day 0 to 4 in the 22 HCV genotype
2/3 infected patients with rs12979860 CT (rs =20.45, P = 0.04).
In contrast to the first phase reduction in HCV RNA, none of the
IL28B-related SNPs or baseline IP-10 predicted the second phase
decline after stratification for the first phase decline.
Both rs12979860 (P = 0.006) and rs12980275 (P = 0.007) were
significantly predictive of RVR, i.e. undetectable HCV RNA at
week 4, whereas the allelic distribution of rs8099917 was not
(P = 0.18). Similarly, baseline plasma IP-10 was lower in patients
achieving RVR than in those who did not (median 222 pg/mL vs.
401 pg/mL, P = 0.008; Mann-Whitney U-test), and, among
homozygous carriers of the rs12979860 and rs8099917 alleles, a
lower baseline IP-10 significantly predicted RVR (Table 2).
Interestingly none of the patients with baseline IP-10 above
600 pg/mL achieved RVR regardless of IL28B genotype.
The distribution of variants at SNP rs12979860 and rs12980275
impacted significantly on SVR among HCV genotype 1 infected
patients (66% vs. 48% for rs12979860 CC and CT/TT, P = 0.04;
65% vs. 47% for rs12980275 AA and AG/GG, P = 0.03; Chi
squared test), but not among variants of rs8099917, although a
non-significant trend towards lower SVR was noted among the 7
homozygous GG carriers as compared to 162 carriers of TT or
TG (29% vs. 54%, P = 0.2). Again, IP-10 significantly augmented
the prediction of SVR among genotype 1 infected for all three
IL28B SNPs with the exception of G allele carriage at rs8099917
(Figure 5). In patients with baseline IP-10 below 150 pg/mL
who were homozygous for favorable SNP genotypes, SVR was
achieved in 85%, 75%, and 75% for rs12979860 CC, rs12980275
AA, and rs8099917 TT, respectively. Notably, achieving RVR was
slightly more predictive of achieving SVR (91%; Table 3) than
combinations of IL28B and baseline IP-10. This remained the case
even when the analysis was restricted to the genotype 1 infected
patients who had no dose reductions, i.e. per-protocol analysis
(92% vs. 83% for RVR and rs12979860 CC and baseline IP-10
below 150 pg/mL respectively; n = 126). In contrast to genotype
1, neither IL28B genotype distribution nor baseline IP-10 levels
predicted SVR among the 71 HCV genotype 2/3 infected
patients.
In multivariate analyses, both IP-10 and C genotype at
rs12979860 were independent predictors of the first phase decline
in HCV RNA (P = 0.009 and P,0.0001 respectively) as well as
RVR (P = 0.048 and P = 0.016 respectively), and RVR was in turn
the only independent predictor of SVR (P = 0.001). RVR
remained the only predictor of SVR when the analysis was
restricted to the fully compliant patients (P = 0.005) reiterating the
importance of monitoring on-treatment response.
Discussion
In spite of the pending introduction of direct antiviral agents
(DAA) in routine clinical practice, interferon-a and ribavirin are
likely to retain pivotal roles in the management of chronic HCV
infection, and thus predicting responsiveness to interferon/
ribavirin-based therapies will remain important. In this setting,
the main finding in the present study was that pretreatment
plasma levels of IP-10 increased the level of prediction of the first
phase decline in HCV RNA among patients carrying IL28B SNP
variants, which translated into improved prediction of RVR and
SVR. Considering the high SVR rates among HCV genotype 1
infected homozygous carriers of CC at rs12979860, AA at
rs12980275, or TT at rs8099917 with baseline IP-10 levels below
150 pg/mL (85%, 76%, and 75% respectively), these patients,
although few in number, should be encouraged to initiate therapy
and may be candidates for shortened duration of therapy in line
with current treatment guidelines considering the high likelihood
of achieving RVR [24,25]. Additionally, these patients may be
suitable for initial inclusion in pending trials with interferon-free
DAA regimes, because of the favorable odds of successful salvage
therapy with interferon in the event of development of resistance
towards these new therapeutic agents.
The finding that IL28B variants primarily impact on the first
phase decline of HCV RNA [26], as previously reported for IP-10
[20], suggests that both IL28B variants and IP-10 are linked to the
antiviral effectiveness of peg-IFN and ribavirin in the blocking of
the production or release of infectious virions rather than on the
clearance of HCV infected cells. The risk alleles, T at rs12979860,
or G at rs12980275 and rs8099917, were found to be significantly
associated with modest elevations of baseline IP-10 levels. This
finding is in line with the recent report by Honda et al. that G at
rs8099917 entails higher intrahepatic expression of a panel of 37
representative ISGs not including IP-10 [13], which is typically
observed in patients who respond less favorably to treatment [27].
The elevated baseline induction of ISGs among risk allele carriers
may explain why these alleles are associated with a lower viral load
observed in our study among patients with chronic HCV infection,
corroborating previous reports [8,11].
Our finding that homozygous CC at rs12979860, AA at
rs12980275, and TT at rs8099917 were significantly more
common in the setting of HCV genotype 2 or 3 infection than 1
in a population consisting only of Caucasian patients confirms and
extends the findings reported by McCarthy et al. [11]. Indeed, the
proportion of CC at rs12979860 among HCV genotype 2 and 3
infected patients (56% and 67%, respectively) in our study is
higher than the reported prevalence in HCV uninfected
Caucasians (,40%), suggesting that this SNP genotype entails a
higher likelihood of development of chronic infection following
exposure to HCV genotype 2 or 3. This observation, however,
may be considered counter-intuitive since homozygous carriage of
CC at rs12979860 was associated with a significantly greater first
phase decline of HCV RNA even in genotype 2/3 infected
patients. A possible hypothesis for these seemingly contradictory
findings is that carriage of the favorable allele C at rs12979860, A
at rs12980275 and T at rs8099917, being associated with a slightly
diminished baseline activation of ISGs, is beneficial for clearance
of all HCV genotypes as reflected by the association with a greater
first phase decline in HCV RNA during therapy irrespective of
Table 3. Sensitivity, specificity, positive and negative
predictive values of the likelihood achieving SVR among
patients infected with HCV genotype 1 (n = 170).
PPV NPV Sensitivity Specificity
rs12979860 CC (n = 44) 66% 52% 32% 81%
Baseline plasma IP-10 66% 52% 33% 81%
,150 pg/mL (n = 44)
CC at rs12979860 or 63% 56% 53% 65%
IP-10,150 pg/mL (n = 75)
CC at rs12979860 and 85% 50% 12% 98%
IP-10,150 pg/mL (n = 13)
RVR (n = 34) 91% 59% 37% 96%
doi:10.1371/journal.pone.0017232.t003
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HCV genotype, but more advantageous for genotype 1 in
comparison to 2/3. In the event of continuous re-exposure to a
variety of HCV genotypes following a possible initial spontaneous
clearance of HCV, as is often the case among intravenous drug
users in addition to the lack of a lasting protective immune
response [28], this skewness will exert selective pressure and over
time lead to an under-representation of these favorable alleles
among genotype 1 patients and an over-representation among 2/3
patients as compared to the non-infected population. This would
be the case even if carriage of this SNP genotype were slightly
beneficial in the event of a single point exposure to HCV genotype
2 or 3. Supportive of this concept is the non-significant trend
towards lower frequency of homozygous CC at rs12979860 (30%)
observed among 27 HCV genotype 2/3 patients infected through
exposure to contaminated blood products as compared to 322
genotype 2/3 patients with other routes of infection in another
study (NORDynamIC trial) [29]. Similarly, in an elderly
population in southern Italy predominantly infected with HCV
genotype 2 likely secondary to past iatrogenic exposure, a non-
significant trend towards a lower proportion of CC at rs12979860
was noted among genotype 2/3 infected patients than among non-
infected controls (37% vs. 42%) [30].
In conclusion, baseline plasma IP-10 is significantly associated
with IL28B-related SNPs, and augments the level of predictiveness
of the first phase decline in HCV RNA, RVR, and final treatment
outcome. Therefore, pre-treatment screening of IL28B genetic
variants, together with measurement of IP-10 in plasma, may
provide useful prognostic information prior to initiating antiviral
therapy for HCV.
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